Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Clicks: 284
ID: 270951
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Sofosbuvir/velpatasvir taken once daily for 12 weeks resulted in high sustained virologic response rates in patients infected with HCV, irrespective of the presence of NS5A resistance-associated variants prior to treatment. Single class NS5A inhibitor resistance, but not sofosbuvir resistance, was d …
Reference Key
c2018journalresistance Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hezode C;Reau N;Svarovskaia ES;Doehle BP;Shanmugam R;Dvory-Sobol H;Hedskog C;McNally J;Osinusi A;Brainard DM;Miller MD;Mo H;Roberts SK;O'Leary JG;Shafran SD;Zeuzem S;;
Journal journal of hepatology
Year 2018
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/29221887
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't Clinical Trial Phase III Multicenter Study Viral Genotype drug resistance drug therapy combination genetic variation high-throughput nucleotide sequencing hepacivirus / genetics* chronic / drug therapy* antiviral agents / administration & dosage* treatment failure hepacivirus / classification sustained virologic response sofosbuvir / administration & dosage* stefan zeuzem chronic / virology* heterocyclic compounds hepacivirus / drug effects* pmid:29221887 doi:10.1016/j.jhep.2017.11.032 christophe hezode nancy reau carbamates / administration & dosage* 4 or more rings / administration & dosage* viral nonstructural proteins / antagonists & inhibitors viral nonstructural proteins / genetics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.